Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viridian Therapeutics, Inc. (Nasdaq: VRDN) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Viridian is a Waltham, Massachusetts-based biopharmaceutical company focused on antibody-based medicines for serious and rare diseases, including thyroid eye disease (TED) and autoimmune conditions involving IGF‑1R, TSHR, and FcRn pathways. Its common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC under the symbol VRDN, as noted in multiple Form 8‑K filings.
Through this page, users can review current and historical Forms 8‑K in which Viridian reports material events such as clinical and regulatory milestones, collaboration and license agreements, financing transactions, and governance matters. Examples disclosed in recent 8‑K filings include public equity offerings, a royalty financing agreement, an amended credit facility, and the collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. Other 8‑Ks furnish press releases reporting quarterly financial results and cash positions, providing insight into the company’s operating expenses, research and development investments, and capital resources.
Investors can also use the filings page to track capital markets activity and share-related arrangements, such as underwriting agreements for public offerings, equity incentive plan amendments, and employee stock purchase plans, all of which appear in Viridian’s current reports and proxy-related disclosures. These documents outline how the company structures its financing, equity compensation, and shareholder approvals as it advances late-stage TED programs and its FcRn inhibitor portfolio.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly understand the main terms of material agreements, the significance of clinical and regulatory announcements, and the implications of financing transactions for Viridian’s runway and strategic plans. For deeper analysis, investors can drill down into specific filings—such as 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available—to examine risk factors, detailed financial statements, and any reported insider buying or selling activity related to VRDN.
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian’s cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei’s development success and Viridian’s ongoing manufacturing obligations.